Bath & Body Works (NYSE:BBWI - Get Free Report)'s stock had its "outperform" rating restated by investment analysts at Raymond James in a research note issued on Tuesday,Benzinga reports. They currently have a $46.00 price objective on the stock, up from their previous price objective of $42.00. Raymond James' price target would indicate a potential upside of 13.38% from the company's current price.
BBWI has been the subject of several other reports. Wells Fargo & Company raised Bath & Body Works from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $42.00 to $48.00 in a research note on Friday, January 10th. TD Cowen increased their target price on shares of Bath & Body Works from $42.00 to $48.00 and gave the company a "buy" rating in a research report on Thursday, December 12th. Piper Sandler raised their price target on shares of Bath & Body Works from $36.00 to $39.00 and gave the stock a "neutral" rating in a research note on Monday, January 6th. Telsey Advisory Group reaffirmed an "outperform" rating and set a $43.00 price objective on shares of Bath & Body Works in a research note on Thursday, February 20th. Finally, Barclays upgraded shares of Bath & Body Works from an "underweight" rating to an "equal weight" rating and increased their price objective for the company from $34.00 to $43.00 in a report on Monday. Six analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $44.44.
Bath & Body Works Stock Performance
Shares of BBWI traded up $0.70 during mid-day trading on Tuesday, hitting $40.57. 4,481,954 shares of the company were exchanged, compared to its average volume of 3,380,829. The stock has a market cap of $8.79 billion, a price-to-earnings ratio of 9.90, a price-to-earnings-growth ratio of 0.92 and a beta of 1.83. Bath & Body Works has a 1-year low of $26.20 and a 1-year high of $52.99. The company has a 50 day moving average of $37.77 and a 200-day moving average of $34.02.
Bath & Body Works (NYSE:BBWI - Get Free Report) last announced its earnings results on Monday, November 25th. The company reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.03. The business had revenue of $1.61 billion during the quarter, compared to analysts' expectations of $1.58 billion. Bath & Body Works had a negative return on equity of 44.03% and a net margin of 12.43%. The business's revenue was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.48 earnings per share. Research analysts anticipate that Bath & Body Works will post 3.3 earnings per share for the current fiscal year.
Institutional Trading of Bath & Body Works
Hedge funds and other institutional investors have recently modified their holdings of the business. Raymond James & Associates grew its position in Bath & Body Works by 6.8% in the 3rd quarter. Raymond James & Associates now owns 89,680 shares of the company's stock valued at $2,863,000 after acquiring an additional 5,706 shares in the last quarter. Sequoia Financial Advisors LLC lifted its holdings in Bath & Body Works by 14.9% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 6,514 shares of the company's stock worth $208,000 after buying an additional 847 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Bath & Body Works by 69.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,092 shares of the company's stock valued at $586,000 after purchasing an additional 7,443 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Bath & Body Works in the 3rd quarter valued at $343,000. Finally, State of Alaska Department of Revenue increased its position in shares of Bath & Body Works by 418.2% during the third quarter. State of Alaska Department of Revenue now owns 127,226 shares of the company's stock worth $4,061,000 after purchasing an additional 102,675 shares in the last quarter. 95.14% of the stock is owned by institutional investors and hedge funds.
Bath & Body Works Company Profile
(Get Free Report)
Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.
Further Reading
- There Are Different Types of Stock To Invest In
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- How to Start Investing in Real Estate
- Palantir Stock Nears Bear Market Territory - Why and What’s Next?
Before you consider Bath & Body Works, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bath & Body Works wasn't on the list.
While Bath & Body Works currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
20 Stocks to Sell Now
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
